Results from a phase 2 study (n = 189) that evaluated safety and efficacy of blinatumomab, a bispecific T-cell engager (BiTE®) molecule, reported that 6.9% of patients with relapsed/refractory acute myeloid leukemia (ALL) experienced ≥ grade 3 ALT elevation [42]. This evidence concerns the gene GPT and acute myeloid leukemia.